Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial
Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, Yao WZ, Ma LJ, Li X, Raiteri L, Sardina M, Gao Y, Wang BS, Zhong NS
Published in The Lancet Respiratory Medicine
Methodology
Multicentre randomised, double-blind, placebo-controlled trial of N-acetylcysteine 600 mg twice daily for one year in Chinese patients with moderate-to-severe COPD, with annual exacerbation rate as the primary endpoint.
Key Findings
N-acetylcysteine 1200 mg/day significantly reduced the annual exacerbation rate compared with placebo, with good tolerability.
Conclusions
High-dose N-acetylcysteine reduces exacerbations in moderate-to-severe COPD.
Limitations
Chinese population only; many participants not on optimal inhaled therapy; industry involvement.
Supplements Studied
N-acetylcysteine 1200 mg/day significantly reduced the annual exacerbation rate compared with placebo.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Zambon (pharmaceutical) and Chinese national research funds
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.